DUN T1

Orally Administered Drug for Type-1 Diabetes

Health Tech & Life Sciences
Active
Seed Meishar, Israel Founded 2017
Last updated 2026-06-18
Total raised
$45K
Last: 2019-12
Stage
Seed
Founded
2017
Headcount
3
HQ
Meishar, Israel
Sector
Health Tech & Life Sciences

About

DUN T1 is an early-stage R&D company that develops an orally administered drug for type 1 diabetes. DUN T1's vision is to develop a proactive approach towards treatment and early diagnosis. DUN T1's novel natural ingredient is patented, safe, and effective.

Funding history · 1 round · $45K total

2019-12
$45K

Q&A

What is DUN T1's primary focus?
DUN T1 is an early-stage R&D company developing an orally administered drug for type 1 diabetes, aiming for a proactive approach to treatment and early diagnosis.
When was DUN T1 founded?
DUN T1 was founded in July 2017.
How much funding has DUN T1 raised to date?
DUN T1 has raised a total of $45,000 USD.
When was DUN T1's last funding round and who invested?
DUN T1's last funding round was in December 2019, with investment from Fundit.
Does DUN T1 hold any patents?
Yes, DUN T1 holds one patent for its novel natural ingredient.
Who are the founders of DUN T1?
The founders of DUN T1 are Daniella Givon (CEO & Head of R&D), Raanan Margalit (Head of Pre-Clinical Studies), and Nadav Shraibom (Head of Strategy Affairs).
What is DUN T1's current product stage?
DUN T1's product is currently in the R&D stage.

Team · 3

Founder · CEO & Head of R&D
LinkedIn ↗
Founder · Head of Pre-Clinical Studies
LinkedIn ↗
Founder · Head of Strategy Affairs
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Commerce & RetailDistribution ChannelsDistributorHealthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B2C

Highlights

1 Patents

Tags

patientschildrenpharma-companiespharmaceuticalsdrug-discoverychronic-patientschronic-diseasetreatmentsnatural-active-ingredientsdiabetesoral-drugs
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)